Fintel reports that on July 29, 2025, William Blair downgraded their outlook for Neogen (NasdaqGS:NEOG) from Outperform to ...

Onvansertib combined with standard care showed up to 49% confirmed ORR in RAS-mutated colorectal cancer, with early signs of ...

Data analytics firm Verisk said on Wednesday it will buy AccuLynx, which makes software for roofing contractors, for $2.35 ...

Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing ...

Vinay Prasad, head of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA), ...

But while many analysts presented a bullish case for the company's turnaround, not all investors are sold on Niccol and his ...

Gain insights into Watsco, Inc.'s Q2 2025 performance, including record margins, tech-driven growth, and its strategic focus on overcoming market ...

Data analytics provider Verisk is acquiring SaaS platform AccuLynx for $2.35bn in cash, the company said in a statement. The ...

Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.

Kapoor elaborated that data and AI-led revenue increased 17% year-over-year, now accounting for 54% of total revenue, and noted "robust double-digit expansion of our sales pipeline this past quarter ...

Cardiff Oncology has reported updated results from its phase 2 colorectal cancer trial, laying out data that it believes can ...